The move is supported by iRhythm investors and disappointed Dexcom’s shareholders.

The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.

Douglas Devine will take over as interim CEO as iRhythm tries to resolve reimbursement challenges and roll out the next generation of its Zio remote cardiac monitor with an updated artificial intelligence system.

The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.